Scancell

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OrsoBio Splurges With Four Concurrent L

Kicking Protocols Down The Road I remember an uncomfortable project team meeting as a commercial representative on a big pharma development program. The meeting was convened to discuss and remedy the